Clinical trials: B-Lymphocytic Leukemia, Chronic
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia.
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT04502394
- Testing
- KRT-232, acalabrutinib
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- Kartos Therapeutics, Inc.
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
This study is for patients who have lymphoma or leukemia that has come back or has not gone away after treatment. Because there is no standard treatment for this cancer, patients are being asked to volunteer for a gene transfer…
- Conditions
- Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL
- Trial name
- NCT03774654
- Testing
- CD19.CAR-aNKT cells
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Baylor College of Medicine
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- SAGAN (NCT01853631)
- Testing
- Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
This pilot phase II trial studies how well high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil work in preventing graft versus host disease in patients with hematological malignancies undergoing myeloablative or…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03128359
- Testing
- Busulfan, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- City of Hope Medical Center
Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Participants will be randomized to SCH 727965 or a comparator drug (bortezomib for mantle cell lymphoma [MCL] or alemtuzumab for B cell chronic lymphocytic leukemia [B CLL]).
- Trial name
- NCT00871546
- Testing
- SCH 727965, Bortezomib, Alemtuzumab
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003451
- Testing
- recombinant interferon alfa, recombinant interleukin-12
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
- Trial name
- NCT03185494
- Testing
- anti-CD19/22-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Leukemia, Lymphoma
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00019656
- Testing
- perifosine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003956
- Testing
- fluorouracil, leucovorin calcium, lonafarnib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Trial name
- NCT05943496
- Testing
- Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloproliferative Disorders, Leukemia
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00068523
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Lymphocytic Leukemia
MEOI and HRQoL in CLL Patients Treated With BTKis
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase…
- Trial name
- NCT04938141
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002779
- Testing
- fludarabine phosphate, octreotide acetate
- Where
- 20 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia, Lymphocytic, Chronic
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)
- Trial name
- NCT00055146
- Testing
- ONTAK
- Where
- 14 sites in United States, Argentina and 3 more
- Volunteers
- 41 people
- Sponsor
- Eisai Inc.
Richter Transformation
R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL
This is an investigator-initiated Phase 2 study, which combines R-EDOCH with Ibrutinib to treat patients with Ritcher Transformation in consideration of DLBCL and CLL components both could being targeted at the same time.
- Trial name
- BDHRT001 (NCT04992377)
- Testing
- R-EPOCH in Combination With Ibrutinib
- Where
- 11 sites in China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
- Trial name
- PERSIST (NCT07474051)
- Testing
- UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123
- Where
- 5 sites in Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Non-Hodgkin Lymphoma
A Rollover Study of CC-122
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 [NCT01421524], CC-122-ST-002…
- Trial name
- NCT05688475
- Testing
- CC-122, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb